Study of xaluritamig for metastatic prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug called xaluritamig for men with metastatic prostate cancer that is resistant to hormone therapy. It is designed for those who have already tried certain hormone pills and one type of chemotherapy, and aims to see if the drug can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of prostate cancer called adenocarcinoma (not mixed with other types).
- Your cancer has spread to other parts of the body (metastatic) and is still growing despite hormone therapy (castration-resistant).
- You have taken at least one hormone therapy pill (like enzalutamide or abiraterone) and it no longer works.
- You have had only one type of chemotherapy (taxane) for your metastatic castration-resistant prostate cancer.
- Cancer has not spread to your brain, and you have not had certain past treatments (like STEAP1 or CD3 targeted drugs).
- You are not currently on high-dose steroids or other strong immune-suppressing medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
This trial tests a new combination of two drugs for men whose prostate cancer has spread and is no longer controlled by hormone therapy. The study aims to see if this treatment can help shrink tumors or slow the disease.
This trial tests a new drug called xaluritamig for men with advanced prostate cancer that didn't respond well to the standard lutetium treatment. The goal is to see if this drug can help shrink the cancer or slow its growth.
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
This trial tests a new drug, xaluritamig, given with standard hormone therapy for men with prostate cancer that has spread to other parts of the body (metastatic) and is still sensitive to hormone therapy. It aims to see if the combination is safe and works better than hormone therapy alone.
This study tests an experimental drug called xaluritamig given before surgery for men with localized prostate cancer that is intermediate or high risk. The goal is to see if it can help shrink the cancer before the prostate is removed.
Hear when a new Metastatic Castration-resistant Prostate Cancer (mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.